344
Participants
Start Date
August 9, 2021
Primary Completion Date
April 30, 2025
Study Completion Date
October 31, 2025
Extended Release Buprenorphine
XR-BUP administration prior to hospital discharge will increase engagement in OUD care on the 34th day following hospital discharge more than is currently afforded by ACS TAU approaches (e.g., methadone, SL-BUP, and naltrexone).
Treatment as Usual
Community standard medication for opioid use disorder (e.g., methadone, sublingual buprenorphine, naltrexone) initiated prior to hospital discharge.
University of Pittsburgh Medical Center, Pittsburgh
Johns Hopkins Bayview Medical Center, Baltimore
Hennepin Healthcare Research Institute, Minneapolis
Yale New Haven Hospital, New Haven
Massachusetts General Hospital, Boston
Boston University, Boston
Lead Sponsor
National Institute on Drug Abuse (NIDA)
NIH
The Emmes Company, LLC
INDUSTRY
Hennepin Healthcare Research Institute
OTHER